Biogen reprioritizes Alzheimer’s disease resources, discontinues ADUHELM development

Biogen Inc. (Nasdaq: BIIB), a leading pharmaceutical company, today announced a strategic reprioritization of its resources in Alzheimer’s disease (AD), a key therapeutic area expected ... Read More